207 related articles for article (PubMed ID: 15671158)
1. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.
Fiordaliso F; Chimenti S; Staszewsky L; Bai A; Carlo E; Cuccovillo I; Doni M; Mengozzi M; Tonelli R; Ghezzi P; Coleman T; Brines M; Cerami A; Latini R
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2046-51. PubMed ID: 15671158
[TBL] [Abstract][Full Text] [Related]
2. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO.
Sato T; Tanno M; Miki T; Yano T; Sato T; Shimamoto K; Miura T
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):401-8. PubMed ID: 20953685
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury.
Wright GL; Hanlon P; Amin K; Steenbergen C; Murphy E; Arcasoy MO
FASEB J; 2004 Jun; 18(9):1031-3. PubMed ID: 15059965
[TBL] [Abstract][Full Text] [Related]
6. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
Ahmet I; Tae HJ; Juhaszova M; Riordon DR; Boheler KR; Sollott SJ; Brines M; Cerami A; Lakatta EG; Talan MI
Mol Med; 2011; 17(3-4):194-200. PubMed ID: 21170473
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.
Calvillo L; Latini R; Kajstura J; Leri A; Anversa P; Ghezzi P; Salio M; Cerami A; Brines M
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4802-6. PubMed ID: 12663857
[TBL] [Abstract][Full Text] [Related]
8. A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney.
Imamura R; Isaka Y; Sandoval RM; Ichimaru N; Abe T; Okumi M; Yazawa K; Kitamura H; Kaimori J; Nonomura N; Rakugi H; Molitoris BA; Takahara S
Clin Exp Nephrol; 2012 Dec; 16(6):852-62. PubMed ID: 22678524
[TBL] [Abstract][Full Text] [Related]
9. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.
Kiss K; Csonka C; Pálóczi J; Pipis J; Görbe A; Kocsis GF; Murlasits Z; Sárközy M; Szűcs G; Holmes CP; Pan Y; Bhandari A; Csont T; Shamloo M; Woodburn KW; Ferdinandy P; Bencsik P
Pharmacol Res; 2016 Nov; 113(Pt A):62-70. PubMed ID: 27521836
[TBL] [Abstract][Full Text] [Related]
10. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia.
Fantacci M; Bianciardi P; Caretti A; Coleman TR; Cerami A; Brines M; Samaja M
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17531-6. PubMed ID: 17090665
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling.
Ghaboura N; Tamareille S; Ducluzeau PH; Grimaud L; Loufrani L; Croué A; Tourmen Y; Henrion D; Furber A; Prunier F
Basic Res Cardiol; 2011 Jan; 106(1):147-62. PubMed ID: 20981553
[TBL] [Abstract][Full Text] [Related]
12. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion.
Tada H; Kagaya Y; Takeda M; Ohta J; Asaumi Y; Satoh K; Ito K; Karibe A; Shirato K; Minegishi N; Shimokawa H
Cardiovasc Res; 2006 Aug; 71(3):466-77. PubMed ID: 16781691
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.
Ahmet I; Tae HJ; Brines M; Cerami A; Lakatta EG; Talan MI
J Pharmacol Exp Ther; 2013 Jun; 345(3):446-56. PubMed ID: 23584743
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat.
King VR; Averill SA; Hewazy D; Priestley JV; Torup L; Michael-Titus AT
Eur J Neurosci; 2007 Jul; 26(1):90-100. PubMed ID: 17614942
[TBL] [Abstract][Full Text] [Related]
15. Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury.
Imamura R; Okumi M; Isaka Y; Ichimaru N; Moriyama T; Imai E; Nonomura N; Takahara S; Okuyama A
Cell Transplant; 2008; 17(1-2):135-41. PubMed ID: 18468243
[TBL] [Abstract][Full Text] [Related]
16. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.
Lipsic E; van der Meer P; Henning RH; Suurmeijer AJ; Boddeus KM; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
J Cardiovasc Pharmacol; 2004 Oct; 44(4):473-9. PubMed ID: 15454856
[TBL] [Abstract][Full Text] [Related]
17. Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model.
Kitamura H; Isaka Y; Takabatake Y; Imamura R; Suzuki C; Takahara S; Imai E
Nephrol Dial Transplant; 2008 May; 23(5):1521-8. PubMed ID: 18194980
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin protects myocardium against ischemia-reperfusion injury under moderate hyperglycemia.
Jun JH; Jun NH; Shim JK; Shin EJ; Kwak YL
Eur J Pharmacol; 2014 Dec; 745():1-9. PubMed ID: 25446919
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin protects against doxorubicin-induced heart failure.
Ammar HI; Saba S; Ammar RI; Elsayed LA; Ghaly WB; Dhingra S
Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2413-21. PubMed ID: 21984540
[TBL] [Abstract][Full Text] [Related]
20. Myocardial reperfusion injury management: erythropoietin compared with postconditioning.
Tamareille S; Ghaboura N; Treguer F; Khachman D; Croué A; Henrion D; Furber A; Prunier F
Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2035-43. PubMed ID: 19617412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
